サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795392

ワクチン研究の世界市場

Vaccine Research

出版日
ページ情報
英文 172 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
ワクチン研究の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 172 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ワクチン研究の世界市場は2030年までに738億米ドルに達する見込み

2024年に394億米ドルと推定されるワクチン研究の世界市場は、2024年から2030年にかけてCAGR 11.0％で成長し、2030年には738億米ドルに達すると予測されます。本レポートで分析しているセグメントの1つである公的ワクチン研究は、CAGR 12.3％を記録し、分析期間終了時には518億米ドルに達すると予測されています。民間ワクチン研究分野の成長率は、分析期間中CAGR 8.3%と推定されます。

米国市場は104億米ドル、中国はCAGR 10.0％で成長すると予測

米国のワクチン研究市場は2024年に104億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに113億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは10.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.9%と8.9%と予測されています。欧州では、ドイツがCAGR約8.5％で成長すると予測されています。

世界のワクチン研究市場- 主要動向と促進要因のまとめ

ワクチン研究が世界ヘルスおよびバイオメディカル科学における戦略的優先事項である理由とは？

ワクチン研究は現代生物医学の重要な柱となり、公衆衛生の成果、パンデミックへの備え、感染症への世界の対応に直接影響を与えています。COVID-19パンデミックの甚大な影響から世界が回復途上にある中、ワクチン研究への注目はますます高まっており、既存の病原体と新興病原体の両方に対抗するための、科学主導型の機敏な技術革新の必要性が強調されています。歴史的に、ワクチン開発は時間と労力を要するプロセスであり、製品を市場に送り出すまでに10年以上かかることも少なくありませんでした。しかし、近年の世界の健康危機の緊急性は、スケジュールを早め、かつてないほどの資金を動員し、政府、学界、製薬業界間の協力体制を促進しました。こうした開発により、ワクチン研究は反応的な取り組みから積極的な取り組みへと昇華しました。今日、ワクチンはインフルエンザ、麻疹、HIVなどの感染症だけでなく、がん、自己免疫疾患、依存症などの非感染症についても研究されています。世界の相互接続と都市化が進むにつれ、病原体の急速な伝播に伴うリスクは増大しており、ワクチンは疾病予防における最も費用対効果の高い強力な手段の一つとなっています。さらに、世界の健康の公平性の目標は、低所得地域向けの安価で安定した、スケーラブルなワクチンの開発にますます依存しています。したがって、ワクチン研究は、もはや単なる科学的・臨床的事業ではなく、健康の安全保障、経済の回復力、社会の安定を支える世界の緊急課題なのです。

科学技術の進歩は、ワクチン研究の状況をどのように変えているのか？

ワクチン研究の状況は、疾病予防の可能性の限界を拡大する科学的・技術的ブレークスルーの波によって、変容しつつあります。最も画期的な進歩のひとつはmRNAワクチン・プラットフォームの台頭であり、COVID-19危機の際にその有効性が証明され、現在では他の感染症や非感染症についても研究が進められています。このプラットフォームは、迅速な設計と製造、新型株への適応性、スケーラブルな製造を可能にし、パンデミック対応に理想的です。さらに、ウイルスベクター技術、組換えタンパク質サブユニット、ナノ粒子ベースの送達システムにより、研究者は副作用の少ない、より標的を絞った効果的なワクチンを開発できるようになっています。構造生物学と計算モデリングにより、科学者はかつてない精度で抗原を設計できるようになり、免疫原性が向上し、開発リスクが低減しています。アジュバントの技術革新もまた、特に高齢者や免疫不全者などの集団における免疫反応を高めています。ゲノムおよびプロテオミクス技術は、病原体の進化や宿主と病原体の相互作用に関する深い洞察を提供し、次世代ワクチンの設計の指針となっています。人工知能と機械学習は、ワクチン標的の同定、有効性の予測、免疫反応のシミュレーションのために、初期段階の研究に統合されつつあります。ハイスループットスクリーニング、自動化、合成生物学は、開発期間と製造コストを削減しています。これらの技術革新は、ワクチンの性能を向上させるだけでなく、カスタムワクチン、多価ワクチン、さらには幅広い関連病原体を防御できる万能ワクチンへの扉を開くものでもあります。

世界のワクチン研究の取り組みを推進している機関や地域は？

世界のワクチン研究への取り組みは、主要企業、バイオテクノロジー企業、学術研究センター、政府機関のネットワークによって推進されています。北米では、国立衛生研究所（NIH）、疾病対策予防センター（CDC）、多数の大学などの組織が、ファイザー、モデナ、ジョンソン・エンド・ジョンソンなどの民間企業と協力して、ワクチン開発の取り組みを長年リードしてきました。欧州も強力なハブであり、欧州医薬品庁（EMA）、オックスフォード大学、多数のドイツ系バイオテクノロジー企業などの機関が、新規ワクチン・プラットフォームや製造プロセスの研究に貢献しています。アジアでは、中国とインドがワクチン研究開発能力を急速に拡大しており、中国科学院、バーラト・バイオテック、インド血清研究所などの機関が大規模臨床試験と世界のワクチン流通を主導しています。日本と韓国も、慢性疾患や希少疾患のための次世代ワクチンなど、バイオ医薬品のイノベーションに多額の投資を行っています。Gavi、CEPI（Coalition for Epidemic Preparedness Innovations）、世界保健機関（WHO）などの世界連合は、国際的な研究努力の調整、低所得国での臨床試験への資金提供、公平なワクチンアクセスの確保において中心的な役割を果たしています。さらに、多国籍イニシアチブとビル＆メリンダ・ゲイツ財団のような慈善財団を通じて資金提供される共同研究プロジェクトは、地域格差を埋め、開発スケジュールを加速するのに役立っています。このようなセクターや国境を越えたパートナーシップは、知識、リソースを共有し、世界の戦略的連携を図ることで、ワクチン研究の利益を確保するために不可欠です。

ワクチン研究市場の成長と投資を促進する要因は？

ワクチン研究市場の成長は、公衆衛生のニーズ、商機、技術的準備、世界の政策イニシアチブの収束によってもたらされます。最も顕著な原動力のひとつは、感染症の発生頻度と重症度の増加であり、これにより、迅速に開発・展開できる新しいワクチンに対する緊急性が持続的に高まっています。将来のパンデミック（世界的大流行）や、一度は制御下にあると考えられていた疾病の再流行が予測されるため、各国政府や国際保健機関は、国や国際的な準備計画の重要な要素として、ワクチンの技術革新への投資を促しています。同時に、人口の高齢化、都市化の進展、世界の旅行といった人口動態の動向は、感染症にかかりやすい人口を拡大しており、より広範な予防接種戦略の必要性を強めています。また、抗菌薬耐性菌の増加により、抗生物質への依存を減らすためのワクチンのような予防的解決策の模索も強まっています。商業面では、ブロックバスター・ワクチンの成功がワクチン研究開発の経済的可能性を実証し、ベンチャーキャピタルや製薬企業との提携、機関投資家の資金をこの分野に引き寄せています。mRNAプラットフォームやスケーラブルなバイオ製造技術の検証などの技術的進歩は、投資のリスクを軽減し、迅速な製品開発を促しました。さらに、迅速な規制パスウェイ、先進的な市場コミットメント、資金提供のインセンティブといった形での政策的支援が、イノベーションをさらに刺激しています。これらの複合的な力によって、公衆衛生の成果のみならず、生物医学と世界のヘルスケア・システムの将来にとっても中心的な、強固で急速に拡大するワクチン研究市場が形成されつつあります。

セグメント

タイプ（公的ワクチン研究、民間ワクチン研究）;年齢層（小児年齢層、成人年齢層）

調査対象企業の例

  • AstraZeneca
  • Bavarian Nordic
  • BioNTech SE
  • Bharat Biotech
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline（GSK）
  • Inovio Pharmaceuticals
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Valneva SE

AIインテグレーション

検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38298

Global Vaccine Research Market to Reach US$73.8 Billion by 2030

The global market for Vaccine Research estimated at US$39.4 Billion in the year 2024, is expected to reach US$73.8 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. Public Vaccine Research, one of the segments analyzed in the report, is expected to record a 12.3% CAGR and reach US$51.8 Billion by the end of the analysis period. Growth in the Private Vaccine Research segment is estimated at 8.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.4 Billion While China is Forecast to Grow at 10.0% CAGR

The Vaccine Research market in the U.S. is estimated at US$10.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.9% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Vaccine Research Market - Key Trends & Drivers Summarized

Why Is Vaccine Research a Strategic Priority in Global Health and Biomedical Science?

Vaccine research has become a critical pillar of modern biomedical science, directly influencing public health outcomes, pandemic preparedness, and the global response to infectious diseases. With the world still recovering from the profound impacts of the COVID-19 pandemic, the spotlight on vaccine research has intensified, underscoring the need for agile, science-driven innovation to counter both existing and emerging pathogens. Historically, vaccine development was a slow and labor-intensive process, often taking a decade or more to bring a product to market. However, the urgency of recent global health crises has accelerated timelines, mobilized unprecedented funding, and fostered collaborative frameworks between governments, academia, and the pharmaceutical industry. These developments have elevated vaccine research from a reactive to a proactive endeavor. Today, vaccines are being investigated not only for infectious diseases like influenza, measles, and HIV, but also for non-infectious conditions such as cancer, autoimmune diseases, and addiction. As the world becomes more interconnected and urbanized, the risks associated with rapid pathogen transmission are growing, making vaccines one of the most cost-effective and powerful tools in disease prevention. Moreover, global health equity goals are increasingly dependent on the development of affordable, stable, and scalable vaccines for low-income regions. Vaccine research is therefore no longer just a scientific or clinical undertaking but a global imperative that supports health security, economic resilience, and social stability.

How Are Scientific and Technological Advances Transforming the Vaccine Research Landscape?

The vaccine research landscape is undergoing a transformative shift, driven by a wave of scientific and technological breakthroughs that are expanding the limits of what is possible in disease prevention. One of the most revolutionary advancements is the rise of mRNA vaccine platforms, which proved their efficacy during the COVID-19 crisis and are now being explored for other infectious and non-infectious diseases. This platform allows for rapid design and production, adaptability to new strains, and scalable manufacturing, making it ideal for pandemic response. Additionally, viral vector technologies, recombinant protein subunits, and nanoparticle-based delivery systems are enabling researchers to develop more targeted and effective vaccines with fewer side effects. Structural biology and computational modeling are allowing scientists to design antigens with unprecedented precision, increasing immunogenicity and reducing development risks. Adjuvant innovation is also enhancing immune responses, especially in populations such as the elderly or immunocompromised. Genomic and proteomic technologies are providing deeper insights into pathogen evolution and host-pathogen interactions, guiding the design of next-generation vaccines. Artificial intelligence and machine learning are being integrated into early-stage research to identify vaccine targets, predict efficacy, and simulate immune responses. High-throughput screening, automation, and synthetic biology are reducing development timelines and production costs. Together, these innovations are not only improving vaccine performance but also opening the door to custom, multivalent, and even universal vaccines capable of protecting against a broad array of related pathogens.

Which Institutions and Geographies Are Driving Global Vaccine Research Efforts?

Global vaccine research efforts are being powered by a network of leading institutions, biotech companies, academic research centers, and government bodies that collectively span the globe. In North America, organizations such as the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and numerous universities have long led vaccine development efforts in collaboration with private firms like Pfizer, Moderna, and Johnson & Johnson. Europe is also a strong hub, with institutions such as the European Medicines Agency (EMA), the University of Oxford, and numerous German biotech companies contributing to research on novel vaccine platforms and manufacturing processes. In Asia, China and India have rapidly expanded their vaccine R&D capabilities, with institutions like the Chinese Academy of Sciences, Bharat Biotech, and the Serum Institute of India leading large-scale clinical trials and global vaccine distribution. Japan and South Korea are also investing heavily in biopharmaceutical innovation, including next-generation vaccines for chronic and rare diseases. Global coalitions such as Gavi, CEPI (Coalition for Epidemic Preparedness Innovations), and the World Health Organization play a central role in coordinating international research efforts, funding trials in lower-income countries, and ensuring equitable vaccine access. Moreover, collaborative research projects funded through multinational initiatives and philanthropic foundations like the Bill & Melinda Gates Foundation are helping bridge regional disparities and accelerate development timelines. These cross-sector and cross-border partnerships are vital in ensuring that vaccine research benefits from shared knowledge, resources, and global strategic alignment.

What Factors Are Driving Growth and Investment in the Vaccine Research Market?

The growth in the vaccine research market is driven by a convergence of public health needs, commercial opportunity, technological readiness, and global policy initiatives. One of the most prominent drivers is the increased frequency and severity of infectious disease outbreaks, which has created a sustained urgency for new vaccines that can be developed and deployed rapidly. Anticipation of future pandemics and the re-emergence of diseases once thought under control are prompting governments and global health organizations to invest in vaccine innovation as a critical component of national and international preparedness plans. At the same time, demographic trends such as aging populations, growing urbanization, and global travel are expanding the population vulnerable to infections, reinforcing the need for broader immunization strategies. The rising incidence of antimicrobial resistance has also intensified the search for preventive solutions like vaccines to reduce reliance on antibiotics. On the commercial side, the success of blockbuster vaccines has demonstrated the financial viability of vaccine R&D, attracting venture capital, pharmaceutical partnerships, and institutional funding into the sector. Technological advancements, such as the validation of mRNA platforms and scalable biomanufacturing techniques, have de-risked investment and encouraged rapid product development. Additionally, policy support in the form of fast-track regulatory pathways, advanced market commitments, and funding incentives is further stimulating innovation. These combined forces are creating a robust and rapidly expanding vaccine research market that is central not only to public health outcomes but also to the future of biomedical science and global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Vaccine Research market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Public Vaccine Research, Private Vaccine Research); Age Group (Pediatric Age Group, Adult Age Group)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AstraZeneca
  • Bavarian Nordic
  • BioNTech SE
  • Bharat Biotech
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi Pasteur
  • Serum Institute of India
  • Sinovac Biotech
  • Takeda Pharmaceutical
  • Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Vaccine Research - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Pandemic Preparedness Throws the Spotlight on Scalable and Rapid Vaccine Research Platforms
    • Surge in Government and Philanthropic Funding Spurs Acceleration of Early-Stage Vaccine Development
    • Here's How mRNA and Next-Gen Platform Technologies Are Transforming the Vaccine R&D Landscape
    • Increased Focus on Zoonotic and Emerging Pathogens Strengthens the Business Case for Broad-Spectrum Vaccine Candidates
    • Advancements in AI and Computational Biology Propel Growth in Antigen Discovery and Immunogenicity Prediction
    • Here's the Story: How Modular Clinical Trial Designs Are Streamlining Vaccine Research Timelines
    • Rising Demand for Universal and Multivalent Vaccines Expands the Scope of Multi-Pathogen Research Initiatives
    • Technological Progress in Adjuvants and Delivery Systems Enables Improved Efficacy and Dose Sparing
    • Growth in Oncology and Therapeutic Vaccines Opens New Avenues for Personalized Vaccine Research
    • Decentralized and Remote Trial Models Sustain Research Continuity Amid Global Health Disruptions
    • Equity and Global Access Considerations Drive Interest in Heat-Stable and Low-Cost Vaccine Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Vaccine Research Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Public Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Public Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Private Vaccine Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Private Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Pediatric Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Pediatric Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Adult Age Group by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Adult Age Group by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 20: USA Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • JAPAN
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 29: Japan Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Japan Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Japan 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • CHINA
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: China 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 38: China Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • EUROPE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Vaccine Research by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Vaccine Research by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • FRANCE
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 50: France Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: France Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: France 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 53: France Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • GERMANY
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 56: Germany Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Germany Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Germany 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 62: Italy Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Italy Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Italy 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 68: UK Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: UK Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: UK 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 71: UK Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Rest of Europe 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Vaccine Research Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Asia-Pacific 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 86: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of World Historic Review for Vaccine Research by Type - Public Vaccine Research and Private Vaccine Research Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of World 16-Year Perspective for Vaccine Research by Type - Percentage Breakdown of Value Sales for Public Vaccine Research and Private Vaccine Research for the Years 2014, 2025 & 2030
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Vaccine Research by Age Group - Pediatric Age Group and Adult Age Group Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Vaccine Research by Age Group - Percentage Breakdown of Value Sales for Pediatric Age Group and Adult Age Group for the Years 2014, 2025 & 2030

IV. COMPETITION